NDC 51662-1418
Nalbuphine Hci 20 mg per 1 mL injection, solution
On the label: HF Acquisition Co. LLC. DBA HealthFirst. It's repackaged: HF Acquisition Co. LLC. DBA HealthFirst rebottles it from Hospira, Inc.'s NDC 0409-1467.
Where the pills inside were made
| Factory | Where | Role | Last FDA inspection |
|---|---|---|---|
| Hospira, Inc. | Rocky Mount, NC, United States | Makes it, tests it, packages it and labels it | No problems foundFeb 7, 2025 · 11 inspections, 3 with FDA action |
Repackaging site
- HF Acquisition Co LLC, Mukilteo, WA, United States · relabels it
Recalls
- Nov 21, 2012 · Class II · Hospira, Inc.
Lack of Assurance of Sterility: Complains of a loose crimp applied to the fliptop vial; and a missing stopper and flip cap were received and therefore sterility cannot be assured.
Lots: Lot #: 11-293-DK, Exp 05/01/13
Class I recalls are the most serious; Class III the least. A recall covers specific lots, listed on each recall.
Product details
- Generic drug
- Nalbuphine: every company that makes it
- Form
- injection, solution, intramuscular; intravenous; subcutaneous
- Strength
- 20 mg per 1 mL
- Approval
- ANDA ANDA070918
- On the market since
- Oct 29, 2019
- Package NDCs
51662-1418-1- Official label
- DailyMed (National Library of Medicine), updated Jan 8, 2025
Got it by mail or from a pharmacy you don't know? Look the pharmacy up on Who Filled My Rx?